Role of SET oncoprotein in hepatocellular carcinoma: An immunohistochemical study.

Autor: Gadallah M; Faculty of Medicine, Pathology, Menoufia University, Shebin El-Kom, Egypt., Asaad NY; Faculty of Medicine, Pathology, Menoufia University, Shebin El-Kom, Egypt., Shabaan M; Faculty of Medicine, Pathology, Menoufia University, Shebin El-Kom, Egypt., Elkholy SS; Menoufia University National Liver Institute, Pathology, Shebin El-Kom, Egypt., Samara MY; Menoufia University National Liver Institute, Pathology, Shebin El-Kom, Egypt., Taie D; Menoufia University National Liver Institute, Pathology, Shebin El-Kom, Egypt.
Jazyk: angličtina
Zdroj: Journal of immunoassay & immunochemistry [J Immunoassay Immunochem] 2022 Jul 04; Vol. 43 (4), pp. 420-434. Date of Electronic Publication: 2022 Feb 13.
DOI: 10.1080/15321819.2022.2034646
Abstrakt: Hepatocellular carcinoma (HCC) is the most prevalent primary cancer of the liver and it is the fourth most common cause of cancer related death worldwide. In Egypt, liver cancer constitutes the most common cause of mortality-related cancer. This study aimed to evaluate the immunohistochemical expression of SET oncoprotein in HCC tissues in comparison with its expression in non tumorous liver tissues and to correlate its expression with clinicopathological parameters. This study investigated 100 cases of HCC (including tumorous and non tumorous tissues). One hundred percent of tumorous and non-tumorous tissues were positive for SET expression. The mean and median values of H -score for SET expression were higher in tumorous than non tumorous tissues ( P = .03). Higher SET expression was significantly correlated with larger tumor size ( P = .012), positive lymphovascular invasion ( P = .028), and shorter overall survival ( P < .001). SET expression in tumor tissues is the most independent factor to affect the overall survival of HCC patients. SET plays a role in hepatocarcinogenesis proved by the increase of SET expression from non-tumorous to tumorous tissues. Also, SET can be used as a prognostic indicator and a novel target therapy in HCC patients.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje